Under the agreement, Cologuard promotional efforts will be expanded efforts through the use of Ironwood’s clinical sales specialists. Ironwood will be compensated from the net sales generated from the physicians on whom they call. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.
Cologuard is the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer.
More articles on GI/endoscopy:
Gastroenterology technology company to know: Exalenz Biosciences
26 gastroenterologists making headlines – March 10, 2015
Vegetarian diet associated with reduced CRC risk
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
